ArticleResuscitation plus2025
Intestinal fatty acid-binding protein as a marker of prognosis and non-occlusive mesenteric ischemia in refractory cardiac arrest patients: a pilot study.
Article in Resuscitation plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- DECT-based stratification of nonocclusive mesenteric ischemia using bowel-wall iodine concentration: a prospective single-center cohort.European radiology experimental · 2026Article
- Fatty acid-binding protein 2 in inflammatory bowel disease: mechanistic insights and translational perspectives.Frontiers in medicine · 2026Review
- Plasma levels of intestinal fatty acid-binding protein and citrulline are not associated with severe upper gastrointestinal ischemic lesions after out-of-hospital cardiac arrest: an ancillary study of the ENTRACT trial.Resuscitation plus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The neurological prognostication is crucial for the management of refractory out-of-hospital cardiac arrest (OHCA) patients. Despite treatment advances, ischemia-reperfusion brain injury remains a critical factor affecting neurological outcomes. This study evaluated the utility of intestinal fatty acid-binding protein (I-FABP) and its relationship with non-occlusive mesenteric ischemia (NOMI) for neurological prognostication, comparing patients with refractory cardiac arrest treated with extracorporeal cardiopulmonary resuscitation (ECPR) compared to those treated with conventional CPR. Methods: This is a single-center prospective pilot study. We compared I-FABP levels in OHCA patients recruited from June 2022 to October 2023. Blood samples for I-FABP examination were collected at admission, 24, and 48 h and analyzed against 30-day neurological outcomes and NOMI occurrence. ROC analysis determined I-FABP cut-off values for predicting poor neurological outcomes (Cerebral Performance Category (CPC) 3-5) in ECPR and CPR groups. Results: Among the 68 patients admitted for OHCA, 22 received ECPR and 46 conventional CPR. I-FABP cut-off values for predicting poor neurological outcomes were: at admission > 0.95 ng/mL for ECPR vs. 1.64 ng/mL for CPR (AUC 0.55 vs. 0.38); at 24 h > 0.04 ng/mL vs. 0.4 ng/mL (AUC 0.7 vs. 0.51); at 48 h > 0.18 ng/mL vs. 0.53 ng/mL (AUC 0.77 vs. 0.41). However, compared to NSE AUCs, I-FABP showed significantly worse outcomes prediction in all time points.I-FABP was unreliable in predicting neurological outcomes and also showed no consistent elevation in NOMI patients. Conclusion: Compared to neuron-specific enolase, I-FABP does not appear to be a predictor of outcome in patients with refractory cardiac arrest. Clinical manifestations of NOMI are not consistently associated with elevated I-FABP levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.